• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Quanterix Corporation

    4/15/24 4:00:49 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $QTRX alert in real time by email
    DEFA14A 1 tm242735d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.                    )

     

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ¨ Preliminary Proxy Statement
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨ Definitive Proxy Statement
    x Definitive Additional Materials
    ¨ Soliciting Material under §240.14a-12

     

    Quanterix Corporation
    (Name of Registrant as Specified In Its Charter)
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check the appropriate box):
    x No fee required.
    ¨ Fee paid previously with preliminary materials.
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

    GRAPHIC

    www.investorvote.com/QTRX Step 1: Go to www.investorvote.com/QTRX. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.investorvote.com/QTRX or scan the QR code — login details are located in the shaded bar below. The Sample Company 2024 Stockholder Meeting Notice 03ZGYC + + Important Notice Regarding the Availability of Proxy Materials for the Quanterix Corporation Stockholder Meeting to be held on June 3, 2024. Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on at the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2024 proxy statement and our 2023 annual report to stockholders are available for viewing, printing and downloading at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 22, 2024 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. Votes submitted electronically must be received by 1:00 am, Eastern Time, on June 3, 2024. MMMMMMMMMMMM MMMMMMMMM MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ 1234 5678 9012 345 C 1234567890 COY MMMMMMM 000001

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/QTRX. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Quanterix Corporation” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by May 22, 2024. Quanterix Corporation’s Annual Meeting of Stockholders will be held on June 3, 2024, at 10:00 a.m. Eastern Time, at 900 Middlesex Turnpike, Building 1, Billerica, MA 01821. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR all nominees and FOR Proposals 2 and 3. 1. Election of Directors: 01 - Karen A. Flynn 02 - Martin D. Madaus, Ph.D. 2. To approve, by a non-binding advisory vote, the compensation of our named executive officers, as disclosed in the proxy statement. 3. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. 2024 Stockholder Meeting Notice

    Get the next $QTRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTRX

    DatePrice TargetRatingAnalyst
    8/11/2025$5.00Buy → Hold
    Canaccord Genuity
    2/1/2024$30.00Sector Outperform
    Scotiabank
    9/25/2023$25.00 → $32.00Hold → Buy
    Canaccord Genuity
    8/8/2023$30.00Market Perform → Outperform
    SVB Securities
    5/23/2023$13.00 → $27.00Neutral → Buy
    Goldman
    8/15/2022$40.00 → $12.00Buy → Hold
    Canaccord Genuity
    8/9/2022$38.00 → $18.00Outperform → Market Perform
    Cowen
    8/9/2022$35.00 → $15.00Outperform → Mkt Perform
    SVB Leerink
    More analyst ratings

    $QTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sriram Vandana covered exercise/tax liability with 4,395 shares, decreasing direct ownership by 5% to 81,618 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    2/6/26 6:58:51 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by President and CEO Cunningham Everett

    4 - Quanterix Corp (0001503274) (Issuer)

    1/21/26 4:15:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Cunningham Everett

    3 - Quanterix Corp (0001503274) (Issuer)

    1/21/26 4:08:59 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sriram Vandana bought $19,878 worth of shares (4,150 units at $4.79), increasing direct ownership by 5% to 87,200 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    9/17/25 10:24:11 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/13/25 4:39:15 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/10/25 4:08:44 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    SEC Filings

    View All

    SEC Form S-8 filed by Quanterix Corporation

    S-8 - Quanterix Corp (0001503274) (Filer)

    1/15/26 4:53:09 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Leadership Update, Financial Statements and Exhibits

    8-K - Quanterix Corp (0001503274) (Filer)

    1/8/26 4:46:24 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form S-8 filed by Quanterix Corporation

    S-8 - Quanterix Corp (0001503274) (Filer)

    12/22/25 4:15:56 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quanterix downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Quanterix from Buy to Hold and set a new price target of $5.00

    8/11/25 9:55:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on Quanterix with a new price target

    Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00

    2/1/24 6:32:54 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously

    9/25/23 9:03:48 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection

    Submission utilizes the comprehensive five-analyte panel and algorithm that formed the basis for Quanterix's LucentAD® Complete LDT Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test for Alzheimer's disease (AD). This submission represents a significant milestone in the Company's mission to provide superior, non-invasive, high-performance diagnostic tools to aid in the evaluation of patients with cognitive symptoms for possible AD. The multi-analy

    2/3/26 8:33:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling

    Analysis of Subjective Cognitive Decline (SCD) cohort indicates that combining biomarkers representing four key biological axes—amyloid, tau, neurodegeneration, and neuroinflammation—provides a superior window into disease progression at the earliest stages Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the high impact journal JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842215. The study, led by researchers at Amsterdam UMC, followed a cohort of nearly 300 individuals for up to 15 years. The findings demonstr

    1/21/26 8:33:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15, 2026, inducement grants (the "Inducement Grants") were made to four employees in connection with the commencement of their employment. The Inducement Grants consist of 88,050 restricted stock units ("RSUs") representing 88,050 shares of Quanterix common stock and options to purchase ("Options") an aggregate of 125,745 shares of Quanterix common stock at an exercise price of $7.95 per share, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date

    1/16/26 4:01:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

    Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets. Under the terms of the amended merger agreement announced on April 29th, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash, in the aggregate, to holders of Akoya shares and other Akoya equity awards. Masoud Toloue, PhD, Chief Executive Officer of Quanterix, said

    7/8/25 9:07:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Financials

    Live finance-specific insights

    View All

    Quanterix Releases Financial Results for the Third Quarter of 2025

    Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the third quarter ended September 30, 2025. "During the third quarter, we delivered on our revenue expectations despite challenging market conditions," said Masoud Toloue, Chief Executive Officer of Quanterix. "Equally important, we achieved key integration milestones from our Akoya transaction — keeping us firmly on track to realize $85 million in annualized synergies and reach cash flow break-even in 2026. Together, we have built a stronger, more scalable company with the foundation to drive sustained growth,

    11/10/25 4:01:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025

    Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November 10, 2025, at 4:30 p.m. E.T., to discuss its third quarter 2025 financial results. Quanterix will issue a press release regarding its third quarter 2025 financial results prior to the conference call on Monday, November 10, 2025, after the market closes. The press release will be posted on the Quanterix website at http://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 3186071. Interested investors can also acces

    11/3/25 7:00:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix Releases Financial Results for the Second Quarter of 2025

    Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. "Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market," said Masoud Toloue, CEO of Quanterix. "We have built a franchise that is generating approximately $100 million of consumables revenue, on a pro forma basis, and demonstrating resiliency in the face of near-term challenges in the US academic market. Within the quarter, our Accelerator business reported a net i

    8/7/25 4:06:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $QTRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

    SC 13G/A - Quanterix Corp (0001503274) (Subject)

    11/13/24 12:41:46 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Quanterix Corporation

    SC 13G - Quanterix Corp (0001503274) (Subject)

    6/27/24 2:46:59 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Quanterix Corporation (Amendment)

    SC 13G/A - Quanterix Corp (0001503274) (Subject)

    2/14/24 4:57:53 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials